AEterna Zentaris (NASDAQ: AEZS) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare AEterna Zentaris to related companies based on the strength of its profitability, risk, dividends, earnings, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

2.9% of AEterna Zentaris shares are held by institutional investors. Comparatively, 49.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.3% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AEterna Zentaris and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEterna Zentaris 0 0 3 0 3.00
AEterna Zentaris Competitors 786 2930 6398 144 2.58

AEterna Zentaris currently has a consensus target price of $4.33, indicating a potential upside of 106.35%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.82%. Given AEterna Zentaris’ stronger consensus rating and higher possible upside, analysts plainly believe AEterna Zentaris is more favorable than its rivals.


This table compares AEterna Zentaris and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AEterna Zentaris -1,945.78% -514.64% -85.79%
AEterna Zentaris Competitors -3,665.52% -412.63% -47.59%

Valuation and Earnings

This table compares AEterna Zentaris and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
AEterna Zentaris $1.08 million -$27.36 million -1.16
AEterna Zentaris Competitors $207.36 million -$2.26 million 0.31

AEterna Zentaris’ rivals have higher revenue and earnings than AEterna Zentaris. AEterna Zentaris is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

AEterna Zentaris has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, AEterna Zentaris’ rivals have a beta of 1.67, suggesting that their average stock price is 67% more volatile than the S&P 500.


AEterna Zentaris rivals beat AEterna Zentaris on 8 of the 12 factors compared.

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.